| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02598570 | Lymphoma | Drug: duvelisib | AbbVie|Infinity Pharmaceuticals, Inc. | Phase 1 | 2015-11-01 | 2017-02-03 |
| NCT02095587 | Hepatic Impairment | Drug: IPI-145 | Verastem, Inc. | Phase 1 | 2014-03-01 | 2017-02-21 |
| NCT02711852 | Hematologic Malignancy | Drug: Duvelisib | Verastem, Inc. | Phase 2 | 2016-04-01 | 2017-03-07 |
| NCT02783625 | Lymphoma|Relapsed/Refractory T-cell Lymphomas | Drug: Romidepsin|Drug: Bortezomib|Drug: duvelisib | Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute|Stanford University | Phase 1 | 2016-05-01 | 2017-03-02 |
| NCT02292225 | Lymphocytic Leukemia, Chronic|Lymphoma, Small Lymphocytic | Drug: IPI-145 (duvelisib)|Drug: Obinutuzumab | Verastem, Inc. | Phase 1 | 2015-02-01 | 2017-02-21 |
| NCT01882803 | Indolent Non-Hodgkin Lymphoma | Drug: IPI-145 (duvelisib) | Verastem, Inc. | Phase 2 | 2013-05-01 | 2017-02-21 |
| NCT02576275 | Indolent Non-Hodgkin's Lymphoma|Follicular Lymphoma|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma | Drug: Duvelisib|Drug: Placebo|Drug: Rituximab|Drug: Bendamustine | Verastem, Inc. | Phase 3 | 2015-12-01 | 2017-02-21 |
| NCT02307461 | Healthy | Drug: IPI-145 (duvelisib)|Drug: IPI-145|Drug: IPI-145 | Verastem, Inc. | Phase 1 | 2014-11-01 | 2017-02-21 |
| NCT02640833 | Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Non-Hodgkin Lymphoma | Drug: Duvelisib|Drug: Venetoclax | AbbVie|Infinity Pharmaceuticals, Inc. | Phase 1 | 2016-07-01 | 2016-07-22 |
| NCT02204982 | Follicular Lymphoma | Drug: IPI-145 (duvelisib)|Drug: Placebo|Drug: Rituximab | Verastem, Inc. | Phase 3 | 2014-09-01 | 2017-02-21 |
| NCT02391545 | CD20+ Follicular Lymphoma | Drug: IPI-145 (duvelisib)|Drug: Rituximab|Drug: Obinutuzumab | Verastem, Inc. | Phase 1|Phase 2 | 2014-12-01 | 2017-03-23 |
| NCT02004522 | Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma | Drug: IPI-145 (duvelisib)|Drug: Ofatumumab | Verastem, Inc. | Phase 3 | 2013-11-01 | 2017-03-23 |
| NCT02049515 | Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma | Drug: IPI-145 (duvelisib)|Drug: Ofatumumab | Verastem, Inc. | Phase 3 | 2013-12-01 | 2017-02-21 |
| NCT01653756 | Asthma | Drug: IPI-145, a PI3K Inhibitor|Drug: Placebo to match IPI-145 | Verastem, Inc. | Phase 2 | 2012-07-01 | 2017-02-21 |
| NCT01476657 | Hematologic Malignancies | Drug: IPI-145 (duvelisib) | Verastem, Inc. | Phase 1 | 2011-10-01 | 2017-02-21 |
| NCT01836861 | Healthy | Drug: IPI-145 | Verastem, Inc. | Phase 1 | 2013-03-01 | 2017-02-21 |
| NCT01549106 | Healthy Volunteers | Drug: IPI-145|Drug: Placebo | Verastem, Inc. | Phase 1 | 2011-08-01 | 2017-02-21 |
| NCT01851707 | Rheumatoid Arthritis | Drug: IPI-145|Drug: Placebo | Verastem, Inc. | Phase 2 | 2013-04-01 | 2017-02-21 |
| NCT01871675 | Lymphoma|Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma|T-cell Lymphoma | Drug: IPI-145|Drug: Rituximab|Drug: Bendamustine | SCRI Development Innovations, LLC|Infinity Pharmaceuticals, Inc. | Phase 1 | 2013-05-01 | 2016-07-07 |
| NCT02605694 | Lymphoma | Drug: Duvelisib|Drug: Rituximab|Drug: R-CHOP|Drug: Prednisone | Verastem, Inc. | Phase 2 | 2015-12-01 | 2017-02-21 |
